普利製藥(300630.SZ):注射用伏立康唑獲得烏克蘭衞生部上市許可
格隆匯6月4日丨普利製藥(300630.SZ)公佈,公司於近日收到了烏克蘭衞生部簽發的注射用伏立康唑200mg的上市許可。
適應症:伏立康唑是一種廣譜的三唑類抗真菌藥,治療侵襲性麴黴病,非中性粒細胞減少患者中的念珠菌血症,對氟康唑耐藥的念珠菌引起的嚴重侵襲性感染(包括克柔念珠菌),由足放線病菌屬和鐮刀菌屬引起的嚴重感染,主要用於進展性可能威脅生命的真菌感染患者的治療,預防接受異基因造血幹細胞移植(HSCT)的高危患者中的侵襲性真菌感染。
近日,公司收到烏克蘭衞生部的上市許可,標誌着普利製藥具備了在烏克蘭銷售注射用伏立康唑的資格,將對公司拓展烏克蘭市場帶來積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.